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Abstract 
The story of antimalarials as antinflammatory drugs dates back few centuries. Chinin, the extract of the Cinchona bark, 
has been exploited since the 18th century for its antimalarial and antifebrile properties. Later, during the Second World 
War, the broad use of antimalarials allowed arguing their antirheumatic effect on soldiers. Since then, these drugs have 
been broadly used to treat Systemic Lupus Erythematosus, but, only recently, the molecular mechanisms of action have 
been partly clarified.  
The inhibitory action on vacuole function and trafficking has been considered for decades the main mechanism of the 
action of antimalarials, affecting the activation of phagocytes and dendritic cells. In addition, chloroquine is also as a 
potent inhibitor of autophagy, providing another possible explanation of its antinflammatory action. However, much 
attention has been recently devoted to the action of antimalarials on the so-called cGAS-STING pathway deputed to the 
sensing of nucleic acid and to the production of type 1 interferons. This pathway is a fundamental mechanism for host 
defence, since it is able to detect microbial DNA and RNA and induce the immune response that will lead to the production 
of interferons. Of note, genetic defects in disposal of nucleic acids lead to inappropriate activation of the cGAS-STING 
pathway and inflammation. These disorders, named type I interferonopathies, represent a valuable model to study the 
antinflammatory potential of antimalarials. 
We will discuss possible development of antimalarials to improve the treatment of type I interferonopathies and, likely 
multifactorial disorders characterised by interferon inflammation, such as systemic lupus erythematosus.    
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Story of antimalarials: from Cinchona bark to Atabrine 
The first antimalarial (AM) drug discovered was the extract from the bark of Chincona tree, a plant of the tropical Latin 
America (Cinchona succirubra). Since the 18th century, use of this extract has become an efficient therapeutic tool to 
eradicate malaria from endemic zones and its efficacy was so evident that Chincona was also used to define intermittent 
fever due to Plasmodium (Francesco Torti “Therapeutice specialis ad febres quasdam perniciosas”, 1712) [1, 2]. For 
almost a century the treatment has been used empirically, by extracting the alkaloid (quinine) from the bark without clear 
indication on purity and concentration. Nonetheless, the efficacy in treating the fever was so noticeable that its use rapidly 
and widely expanded in almost all the world between the 18th and 20th centuries. The purification of quinine represented 
also a great pharmaceutical industry success [3], so that malaria could be considered the first infectious disease treated 
with a pure chemical compound [4].  
In 1820 quinine was finally isolated from the bark [5]. But, only by the end of 1800 strategies for synthesis of quinine 
alkaloids have developed [6] and became an industrial process during the Second World War, when it has strived to 
produce synthetic AM treatments for the soldiers [3]. This also led to the synthesis of acridine, from which mepacrine 
(commercialized as Atabrine) was developed becoming another fundamental AM drug [7].  
In the meanwhile, in the years between the 19th and 20th centuries, the etiopathology of malaria was discovered with the 
identification of Plasmodium and some of the new synthesized compounds could be tested and modified to obtain more 
effective and less toxic drugs, achieving the synthesis of a compound, resochin, later called Chloroquine (CQ), that shows 
a higher efficacy compared to mepacrine [7, 8]. 
During war, the wide use of AM drugs on soldiers allowed discovering their “side” antinflammatory effects, particularly 
on arthritis and skin lesions of rheumatic diseases [9, 10]. Within the middle of 20th century, systematic studies on AMs 
in rheumatic diseases have been performed and scientific evidences were published [11-13]. Since then, AMs have been 
used to treat with success rheumatic disorders, even if, at today, the mechanisms of action of AM drugs as 
antinflammatories and immunomodulators is not completely unravelled. 
 
Interferonopathies: from monogenic Aicardi-Goutieres Syndrome to Systemic Lupus Erythematosus 
Monogenic interferonopathies 
Interferonopathies are a group of disorders arising from inappropriate production of type I interferons. The term 
interferonopathy was firstly proposed to describe the central role of a dysregulated production of type I interferons in the 
pathogenesis of Aicardi Goutieres Syndrome (AGS), spondyloenchondrodysplasia (SPENCD), and cases of systemic 
lupus erythematosus (SLE) [14] Subsequently, IFN-mediated autoinflammatory disorders, such as STING-associated 
vasculopathy with onset in infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and 
Elevated temperature (CANDLE) have been included in this group [15]. These disorders are named autoinflammatory as 
they are characterized by seemingly unprovoked upregulation of innate immunity and inflammation.  
Most of the genes responsible for interferonopathies are involved in mechanisms of recognition and/or metabolism of 
nucleic acids, that physiologically prevent the accumulation of nucleic acids in the cytoplasm (Table 1). 
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Table 1. Diseases with dysregulated interferon pathway a. 
Disease Gene Inheritance Protein function Main symptoms 
Aicardi-Goutières syndrome 
(AGS) 
TREX1, ADAR1 
 
 
RNASEH2, 
SAMHD1 
 
IFIH1 
Autosomal recessive 
/ dominant 
 
Autosomal recessive 
 
 
Autosomal dominant 
Proteins involved 
in 
  recognition and 
metabolism of 
nucleic acids 
Cerebral atrophy, 
leukodystrophy, 
intracranial 
calcifications 
Familial Chilblain Lupus 
(FCL) 
TREX1 
Autosomal 
  recessive / dominant 
3ʹ–5ʹ 
 DNA 
exonuclease 
Cutaneous Lupus 
Erythematosus (LE) 
with recurrent 
chilblains 
STING-associated 
vasculopathy with onset in 
infancy (SAVI) 
TMEM173 
(STING) 
Autosomal dominant 
Adaptor protein 
involved in 
cytosolic 
  DNA sensing 
and type I IFN 
production 
Pulmonary and 
systemic 
inflammation, 
cutaneous 
vasculopathy 
Chronic Atypical 
Neutrophilic Dermatosis with 
Lipodystrophy and Elevated 
Temperature (CANDLE) 
Syndrome 
PSM88 
Autosomal  
recessive 
Part of a multi-
subunit complex 
  involved in 
proteolysis 
Recurrent (daily) 
fever, skin lesions, 
systemic 
inflammation 
Spondyloenchondrodysplasia 
(SPENCD) 
ACP5 
(TRAP) 
Autosomal  
recessive 
Lysosomal 
  phosphatase 
Immune 
dysregulation with 
neurologic 
involvement (mental 
retardation, cerebral 
calcifications) 
Deficiency of ISG15 ISG15 
Autosomal  
recessive 
Negative regulator 
of type I IFN 
  production 
Intracranial 
calcifications, 
seizures, 
susceptibility to 
mycobacteria 
ACP5 Acid Phosphatase 5, Tartrate Resistant; ADAR1 adenosine deaminase acting on RNA 1; IFIH1 IFN-induced helicase C domain-containing 
protein 1 (also known as MDA5); IFN Interferon; ISG15 Interferon-stimulated gene 15; PSMB8 Proteasome subunit beta type-8, RNASEH2 
Ribonuclease H2; SAMHD1 deoxynucleoside triphosphate triphosphohydrolase SAM domain and HD domain 1; TMEM173 transmembrane Protein 
173 (STING Stimulator of interferon genes); TREX1 DNA 3ʹ - repair exonuclease 1.  
a Modified from [16] and [34].  
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The first disease associated with the term “interferonopathy” was the AGS, an early onset progressive brain disease 
associated with increased number of white blood cells in the cerebrospinal fluid and skin lesions (in some cases, the 
disease shows an overlap with SLE), caused by mutations that alters the function of nucleases that degrade DNA (TREX1) 
and DNA:RNA hybrid molecules (RNASE H2 complex) [16-19]. Later, different mutations have been associated with 
other form of AGS: ADAR1, an RNA editing enzyme [20]; SAMHD1, a protein that decreases the availability of cytosolic 
deoxynucleotides (dNTPs) [21]; IFIH1, a cytosolic viral RNA receptor [22, 23]. SAVI syndrome, vasculopathy that 
produces severe skin lesions (face, ears, nose, and digits), is due to activating mutations in the adapter protein Stimulator 
of Interferon Genes (STING), responsible for constitutive type I IFN production [24]. Finally, a different mechanism is 
involved in Interferon stimulated gene-15 (ISG15) disorder, characterized by intracranial calcifications, epilepsy, high 
susceptibility to mycobacterial infections, autoantibodies and elevated levels of interferon and interferon-induced genes. 
In this case, the ISG15 defect affects the suppressive mechanism that tightly regulates the type I interferon cascade, 
resulting in a lack of “switching off”	signal [25]. 
Summarizing, some interferonopathies depend on a defective degradation of endogenous nucleic acids in lysosomes 
and/or in the cell cytoplasm; other diseases arise from a constitutive activation or defective regulation of downstream 
effector molecules in the nucleic acids sensing pathways. This may be highly relevant to the choice of antinflammatory 
agents acting on different points of the interferon pathway.  
Similar to what described for other autoinflammatory diseases, innate immune mechanisms devoted to the sensing of 
danger signals are activated in the absence of exogenous infectious triggers. However, whilst IL1b-associated 
autoinflammatory diseases display little if any involvement of adaptive immunity, interferonopathies can associate with 
secondary activation of B cells and production of autoantibodies. Thus, the dogma that autoinflammatory diseases are not 
characterized by autoimmune phenomena does not apply to all the interferonopathies, which may include 
autoinflammatory disorders as well as diseases with more prominent autoimmune features [26]. 
Although all the interferonopathies are due to mutations in the same pathway, the expression of the defect in different 
tissues and cell compartments may account for a wide clinical spectrum of symptoms, ranging from TORCH-like 
neonatal-onset inflammatory diseases with neurologic and multi-organ involvement to familial systemic lupus 
erythematosus. The finding of a strongly upregulated expression of genes induced by interferon has constituted the basis 
for the definition of the so called Interferon Signature (IS), which has become a powerful screening tool for 
interferonopathies [27]. IS consists in the increased expression of set of genes induced by interferon (Interferon stimulated 
genes, ISGs), which can be analyzed in the peripheral blood through qPCR technique. The median value of the relative 
quantifications provides a “score”, useful to identify a positive or negative IS, and, respectively, if the interferon pathway 
is activated or not [27]. 
Of note, a strong IS can be found in many patients with SLE, supporting the idea that a dysregulated activation of the 
interferons also plays a crucial role in this multifactorial disorder [28].  
For these reasons, much interest has been drawn toward the study of the pathway involved in monogenic 
interferonopathies. Recent studies highlighted the crucial role of the enzyme Cyclic GMP-AMP Synthase (cGAS) as the 
main initiator of the DNA sensing in the cells [29]. Undigested cytoplasmic DNA stimulates cGAS to produce the second 
mediator cyclic GMP-AMP (cGAMP) [30], which in turn leads to activation of STING [31], phosphorylation of TBK1 
and translocation of the transcription factor IRF3 to the nucleus, where it induces the production of type I interferons [32, 
33]. In normal conditions, this sequence of events is meant to sense the presence of viral nucleic acids and to initiate the 
antiviral immune response, sustained by the production of interferons. In monogenic interferonopathies and in SLE, this 
pathway is inappropriately activated producing a chronic inflammatory response. Clinical features common to most 
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interferonopathies may include skin vasculopathy with chilblains and livedo reticularis, interstitial lung disease and 
panniculitis [34]. Neurological, articular and renal involvement is also common. Furthermore, the effect of interferons on 
the bone marrow can be responsible for various degrees of blood cells cytopenia. In some cases, anti-nuclear and anti-
DNA antibodies may result from an abnormal exposure of the immune system to undigested nucleic acids and from a 
chronic stimulation of antibody producing B cells by interferon activated dendritic cells. Even if a number of other 
pathogenic mechanisms may variously contribute to the development of SLE, the amplification of the inflammatory 
response by interferons seems to be a crucial mechanism in the pathogenesis of this disease. Thus, there is much interest 
on the development of pharmacologic approaches to modulate the innate response to nucleic acids in SLE. The study of 
monogenic interferonopathies will provide valuable models to measure the potential of different inhibitors on this 
pathway. 
 
Dysregulated interferon pathway in lupus and other multifactorial rheumatic disorders 
The pathological role of type I interferon pathway has been reported not only for monogenic interferonopathies, but also 
for some multifactorial rheumatic disorders such as systemic lupus erythematosus (SLE) and dermatomyositis (DM). 
SLE is characterized by skin rashes, arthritis, kidney and blood disorders and by the presence of numerous autoantibodies 
(auto-Ab), in particular directed against components of the nucleus, the cytoplasm, the cell surface and against soluble 
molecules such as Ig and coagulation factors [35]. 
In recent years, the role of innate immunity has emerged in the pathogenesis of SLE, and more than 30 genetic variants 
have been associated with SLE diagnosis, including variants of HLA, Fcγ receptor genes, IRF5, STAT4, PTPN22, 
TNFAIP3. Some of those genes are related to regulation of endogenous nucleic acids (e.g. genes identified from the study 
of the AGS as TREX1 and the RNASE H2 family, which, in some cases, are associated with SLE), or TLR-activating 
immune complexes and their downstream signaling molecules. The peculiar feature shared by most of these mechanisms 
is the strong induction of type I IFN [27, 36]. Observations of elevated levels of type I IFN in the blood of patients with 
SLE were initially reported in 1979 [37], but for years a few groups have investigated the role of type I IFN in SLE. In 
2002, the first gene expression data from different studies performed in peripheral blood mononuclear cells (PBMC) from 
lupus patients was reported [38-40]. In the following years, thanks to the development of in vitro and murine models [41, 
42], type I IFN has been identified as a central pathogenic mediator responsible for many of the peculiar features of SLE 
[43, 44]. Moreover, while in viral infections, type I IFN is produced in the initial stage but is not persistent, in patients 
with SLE the type I IFN gene expression signature persists over time [45-47]. Finally, another evidence of a pathogenic 
role for type I IFN in SLE comes from analysis of tissues: the IFN-induced gene transcripts were found in skin and renal 
biopsies and in synovial tissue [48-50]. 
Another condition in which a strong activation of the type I IFN signal occurs is dermatomyositis (DM), an autoimmune 
disease affecting principally the skin and the skeletal muscle, which can be discriminate into juvenile dermatomyositis 
(JDM) and adult dermatomyositis (DM), two different diseases with a different range of additional features and 
complications. In general, adult patients with DM develop frequently interstitial lung disease, showing higher association 
with malignancy and other comorbidities, while children with DM display more vasculopathy, but a better prognosis and 
survival. Despite DM and JDM represent two heterogeneous diseases, they share similar muscle biopsy features and a 
strong IS in the affected tissues [51, 52].  
The evidence of the IFN involvement in the pathogenesis of DM is suggested by different studies that demonstrated the 
abundance of type I IFN–inducible transcripts in blood samples and/or muscle of DM patients [53, 54]. In 2010, 
Salajegheh and collaborators showed that the ISG15 transcript, an interferon-induced gene, is highly present in 
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dermatomyositis muscle, and, in turn, the exposure of muscle cell culture to type I IFN produces molecular features 
similar to those of dermatomyositis muscle [55]. These findings support a crucial role for type I interferons in pathological 
features of DM [56]. One of the well-known mechanism that induces type I IFN production is the trigger of toll-like 
receptors (TLR7 and 9) in plasmacytoid dendritic cells (pDCs), specialized in the production of type I IFN, which resulted 
abundant both in the skin lesions of SLE patients and in the affected muscle cells of DM patients [48, 57]. 
These evidences establish that type I interferon signal represents the pathogenetic mechanism shared by multifactorial 
rheumatic diseases like SLE and DM, making this pathway as a candidate for targeted therapies and a possible source of 
blood biomarkers for disease activity. 
 
Clinical trials of antimalarials in rheumatic disorders 
Even if AMs have been used in rheumatic disorders since decades, knowledge on their antinflammatory mechanisms are 
still evolving, with significant findings obtained in very recent years. These drugs can be considered effective treatments 
for rheumatoid diseases such as rheumatoid arthritis (RA) and SLE and several clinical trials were published, but with 
questionable results due to the small sample sizes using higher drug dosages than those accepted today. 
Only during the last decade, a lot of new clinical trials have been published with larger sample sizes and better design, 
shedding light on efficacy and toxicity of Hydroxychloroquine (HCQ), which showed significant superiority to placebo 
and a low toxicity profile [58]. 
Others AM used are CQ, structurally similar to HCQ, and Quinacrine (QC, also known as Mepacrine), which is much 
less frequently used than the others because of the yellowish skin color caused by treatment [59]. 
Nowadays, the most common used AM drug in rheumatic diseases is HCQ, which covers the most of all AM prescriptions 
for rheumatic disorders [60]. Indeed, numerous clinical trials involved the use of HCQ in rheumatic disorders, both as a 
single treatment and in combination with other antirheumatic drugs (Table 2). Conversely, just few trials of CQ are active, 
and there is no current trial of QC in rheumatic diseases (Table 3) [61]. 
 
Table 2. Clinical trials on Hydroxychloroquine in rheumatic disorders a. 
 
Not yet 
started 
Phase I 
Trials 
Phase II 
Trials 
Phase III 
Trials 
Phase IV 
Trials 
Terminated 
Completed 0 1 2 15 4 2 
Recruiting 1 0 1 1 6 0 
Ongoing 0 0 1 1 0 0 
a source: www.clinicaltrials.gov [61] 
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Table 3. Clinical trials on Chloroquine in rheumatic disorders a. 
 
Not yet 
started 
Phase I 
Trials 
Phase II 
Trials 
Phase III 
Trials 
Phase IV 
Trials 
Terminated 
Completed 0 0 0 5 1 0 
Recruiting 0 0 0 1 0 0 
Ongoing 0 0 0 0 0 0 
a source: www.clinicaltrials.gov [61] 
 
 
Mechanisms of action of antimalarials 
Lysosome and autophagy impairment 
It is well known that lysosomes accomplish their function of digestion of phagocytized exogenous materials, mainly 
thanks to the acid pH inside the organelles themselves. More recently, a role was recognized for lysosomes as important 
players for the clearance of endogenous material. This process, called autophagy, was demonstrated to be genetically 
determined and fundamental for maintaining the homeostasis of the cell, since it allows to degrade or recycle cellular 
components thus providing new material to renew the cell or energy in case of starvation [62-64]. 
AM drugs, such as CQ and HCQ, are acidophile substances that can freely pass through the cell membrane and accumulate 
up to 100 times in the acidic organelles like lysosomes, so that they are indicated as lysosomotropic agents [65-67]. Once 
in the lysosomes, these drugs are protonated and retained in these organelles where they are able to alter morphology and 
pH, thus resulting in an impaired functionality. This implies altered processing of proteins and ingested antigens, and this 
is a significant effect particularly for cells like macrophages, monocytes or dendritic cells since the activity of antigen 
presentation and MHC loading results strongly defective [67, 68]. It seems that the impairment in lysosomal function can 
lead to an altered immune function and subsequent lowered production of pro-inflammatory cytokines, such as IL-1, IL-
6, TNF-a or IFN-g [68, 69]. 
 
TLR9 blockade 
Toll-like receptors (TLRs) are a family of cellular sensors deputed to the binding of several PAMPs, such as proteins or 
nucleic acids. Among the identified human TLRs, TLR9 is an endosomal molecule able to bind to unmethylated DNA 
from pathogens that infect the host cells. The binding between TLR9 and nucleic acids activates a cascade signaling, via 
MyD88, which results in production of type I interferons and other cytokines [70]. In autoinflammatory disorders such 
as SLE, the persistent stimulation with endogenous DNA is thought to cause a continuous activation of the pathway, 
resulting in a dysregulated production of pro-inflammatory cytokines [71, 72]. AMs may influence the activation of TLR9 
by different mechanisms, including the binding to nucleic acids and masking of sequences recognized by TLR9 [73, 74] 
and the modification of lysosomal pH, which can inhibit the recognition of pathogen associated molecular patterns 
(PAMPs) by endosomal TLRs like TLR9 [73, 75]. Notably, targeting of toll-like receptors recently emerged as a possible 
innovative approach to treat SLE [76]. 
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cGAS inhibition 
Recent insights into molecular mechanisms of onset of monogenic disorders like AGS have revealed the involvement of 
the enzyme Cyclic GMP-AMP Synthase (cGAS) as a key molecule [29, 77, 78]. Indeed, as previously discussed, cGAS 
binds DNA and catalyzes the synthesis of cGAMP, a cyclic dinucleotide, that acts as a second messenger and induces the 
production of type I interferons and other pro-inflammatory cytokines, through the adaptor protein Stimulator of 
Interferon Genes (STING) [29]. Recently, a hypothesis of action of AMs on this side has been proposed by unbiased 
studies. Indeed, AMs such as CQ and HCQ are able to inhibit the binding between DNA and cGAS, thus preventing the 
activation of the pathway [9]. 
The finding that quinoline AMs are potent inhibitors of cGAS has opened novel avenues to improve the use of this group 
of medications in the treatment of interferonopathies and SLE.  
 
Pharmacokinetics and pharmacodynamics of antimalarials: can we improve tissue distribution? 
CQ is a 4-amino quinoline drug, largely used in AM chemotherapy. It’s derivative HCQ, in which one of the N-ethyl 
substituents has been beta-hydroxylated, has similar AM activity, however the latter compound is usually preferred for 
treatment of rheumatic diseases, because, at the high doses required for these diseases, it’s ocular toxicity is less frequent 
[79, 80]. 
Both drugs have a very good bioavailability after oral administration and are rapidly absorbed from intramuscular and 
subcutaneous sites. They have an extremely high volume of distribution of 132-261 l/kg and 525±158 l/kg for CQ and 
HCQ respectively; indeed, they are extensively distributed and sequestered in tissues, mostly in liver, spleen, kidney, lung 
and melanin containing cells [81]. Of particular interest is the binding of both drugs to melanin in the pigmented cells of 
the eye. Studies have shown that the corneal disposition of CQ is higher than HCQ [82, 83]. These deposits in the cornea 
are dose dependent and are always reversible after discontinuation of the drug. Retinopathy is another important side 
effect of these AMs [84-86] and is probably related to the binding to melanin in the retinal pigmented epithelium [79]. 
High concentrations are also found in the brain and spinal cord [81]. 
CQ is also significantly accumulated in polymorphonuclear-lymphocytes and to a lesser extent in mononuclear and red 
blood cells and this is particularly interesting in inflammatory diseases. The high concentrations observed in 
polymorphonuclear blood cells are probably related to the presence of acidic lysosomes in which these drugs, that are 
weak bases, are trapped [87]. 
Protein binding is moderate, around 50-60% [88, 89]. Different studies have demonstrated that CQ, HCQ and their 
metabolites are excreted and can be found in breast milk, moreover transplacental passage has been also observed [90, 
91]. 
CQ, as well as HCQ, are extensively metabolized and de-alkylated in the liver by cytochrome P450 enzymes and 
CYP2D8, CYP2D6 and CYP3A4 are the isoforms mainly involved their in metabolism [92]. Desethyl metabolites 
maintain the pharmacological activity [93, 94]. 
Both the compounds and their active hepatic metabolites are excreted mostly by the kidney [95, 96]; hence, the dose 
should be reduced is renal insufficiency, renal excretion can be increased by the acidification of the urines. Small amounts 
are excreted in feces, through the skin, and in breast milk. These agents have a very long elimination half-life (10-24 and 
26-63 days respectively for CQ and HCQ) and are detected in tissues for prolonged periods (up to 5 years) [81]. 
To date, it is possible to measure plasma, serum and whole blood HCQ levels. Several studies have shown the usefulness 
of measurements of HCQ levels in particular in patients with SLE [97-101]. 
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The other AM drug used in interferonophaties is QC (mepacrine), an acridine derivative. QC is usually administered 
orally and is rapidly and completely adsorbed from the gastrointestinal tract [102]. The drug can be also administered 
intralesionary, paralesionary, intravenously, intramuscularly and rectally [103]. Peak plasma levels are reached in 8-12 
hours and steady state is reached by the fourth week. Like CQ and HCQ, quinacrine has a high volume of distribution 
and is concentrated in liver, spleen, lungs and adrenal glands; in the liver, concentrations reach 20,000 times that of 
plasma [104]. The drug is also highly concentrated in the skin, fingernails and hair [103]. Plasma protein binding at 
therapeutic doses is 80-90% and the plasma half-life is five to fourteen days depending on doses regimens [105]. Renal 
elimination is predominant, while small amounts of the drug are excreted in the feaces, sweat and saliva [103]. 
The large volume of distribution of AMs results in therapeutic effects but also leads to toxicity, therefore one of the main 
goals of pharmacology is to specifically target drugs to the cell types responsible for the disease, hence highly increasing 
the safety of the drug. 
To date, a large number of studies have been performed with the aim of specifically targeting drugs: immunoliposomal 
systems with monoclonal antibodies, sugar-dependent systems that take advantages of cell-specific lectins, and receptor-
dependent systems that allow the targeting of cells bearing specifics integrins have been tested [106-110]. However, these 
approaches have limited applications and still need to be set up. 
In rheumatic diseases, cells of the monocyte-macrophage lines are highly involved and should represent a useful target 
for therapeutic agents among which AMs. In these cells the intracellular enzyme human carboxylesterases-1 (hCE-1) is 
high expressed and this is the principal source of the enzyme outside the hepatocytes. Human intracellular 
carboxylesterases are a family of enzymes that convert neutral membrane esters into charged acid products. Needham et 
al [111], developed an interesting model attaching a small esterase-sensitive chemical motif to a wide range of small 
molecules, in a position that does not significantly interfere with the target enzyme-inhibitor interaction. The authors have 
demonstrated that these modified compounds are selectively hydrolyzed in monocytes and macrophages by hCE-1, 
releasing the charged pharmacologically active drug that will be then concentrated in these cell types. The authors 
successfully uses this approach to deliver a wide range of drugs to cells of the monocytes-macrophage lineage. In human 
blood, the effect on monocytes of the modified histone deacetylase inhibitors, are evident at concentration 1000 fold 
lower than those that affect other cells types that do not express hCE-1. It would be of particular interest to apply this 
approach also on AM drugs used in rheumatic diseases. 
 
Chemical structure of antimalarials: can we improve specificity? 
The structural domains of cGAS present two highly attractive drug targets, the catalytic site and a regulatory site, both 
with established key residues in relatively compressed regions and both with known substrates/ligands. The pronounced 
conformational change in the dsDNA bound enzyme compared to apo enzyme lends further enthusiasm to the hypothesis 
that cGAS activity could be inhibited by appropriately -designed small molecules. 
In an effort to identify drugs able to inhibit cGAS activity, researchers performed in silico screening of chemical and drug 
libraries using the publicly available VINA™ and DOCK™ software. Using Computational Analysis with the Autodock 
VINA™ platform, researchers identified HCQ, 9-amino-6-chloro-2-methoxyacridine (ACMA) and Quinacrine (QC) to 
interact at the Zn thumb and spine regions of cGAS, involving simultaneous enzyme and DNA binding. The two main 
binding events, at the Zn thumb and at the spine, appear to occur within 3-10 Angstroms of the amino acids shown by 
mutation to be needed for dsDNA binding. The binding affinity was calculated by AutoDock VINA™ software [112, 
113]. 
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Researchers performed in vitro dose-titration experiments with recombinant cGAS and quantified cGAMP production 
using thin layer chromatography (TLC). Every tested AM compound yielded dose-response curves similar to QC but with 
different inhibitory activities [112]. QC and ACMA were the most potent inhibitors of cGAMP production (low µM 
range); quinine (QN) had very low inhibitory activity, and primaquine (PQ), CQ, and HCQ had intermediate inhibitory 
activities. The computational predicted binding affinities correlated well with the IC50 of AM drugs, validating the 
prediction of their computational analysis. These observations establish that aminoquinoline- and aminoacridine-based 
AMs impair DNA-stimulated cGAS activity (Fig. 1) [112]. 
Furthermore, researchers postulated that AMs could inhibit IFN-β production within the cell, based on a previously known 
fact that cGAS is the key cytosolic DNA sensor required for IFN-β production in THP1 cells in response to DNA [30]. 
Researcher transfected THP1 cells with dsDNA in the presence or absence of different AMs and quantified IFN-β 
expression by quantitative PCR. ACMA, HCQ, and CQ all inhibited IFN-β production by THP1 cells with an IC50 dose 
range of 3 to 25 µM. At the IC50 for QC and HCQ (∼3 and 25 µM, respectively), both cell viability and transfection 
efficiency were unaffected compared with the no-drug control, although some reduction in cell viability and/or 
transfection efficiency was observed at higher doses. In contrast, PQ and QN exhibited 10-fold lower potency. The order 
of AMD inhibitory activity in vitro and in cells was very similar, consistent with DNA/cGAS interaction as the target. 
Interference with other pathways also was noted; although the concentration of HCQ to achieve 50% inhibition of IFN-β 
production was higher than the 1-2 µM detected in the blood of patients, it was reported that HCQ is concentrated 10–
100-fold in the cell during long-term treatment [103]. QC was reported to be more effective than HCQ, and these drugs 
take weeks to months to exert their clinical effect in SLE [103], suggesting that concentration within the cell is required. 
This preliminary study activity relationship suggested that the rational design of more potent and specific cGAS inhibitors 
of the aminoacridine and aminoquinoline families may be possible. The structure activity relationship for AMCA core 
was performed highlighting the fact that substituting at the amine end of acridin-9-amine core with long chains resulted 
in inhibitors with better potency, as compared to cases where substituent are bulky groups. The key of the design lies in 
the torsional freedom of the substituents (Fig 2). 
 
Conclusion and future perspective 
Since the efficacy of various AMs may depend on a quite selective targeting of different mechanisms, ranging from the 
interference with TLR binding in lysosomes to the inhibition of cGAS in the cytosol, future studies are needed to address 
which of these action has the greater antinflammatory potential in SLE. In fact, whilst HCQ has a stronger capacity of 
influencing the phagosome pH and the function of TLR9, mepacrine may be more effective as cGAS inhibitor. Moreover, 
the differential action of AMs may depend also on their concentration that they reach in different cells and compartments. 
Thus, it will be important developing reliable computed chemistry models to predict how molecular changes will affect 
the different mechanisms of action of the drugs, as well as its concentration in tissues and cell compartments. On wet, or 
at a preclinical level, the study of the action of modified AMs in monogenic interferonopathies may provide significant 
knowledge to foster the development of novel drugs.  
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Figures. 
 
Figure 1. Validated IC50 (µM) of antimalarials (extracted from An J et al, J Immunol 2015 [112]) 
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Figure 2. Possible substitutions at the amine end of acridin-9-amine core and corresponding IC50 (µM) and toxicity (µM). 
Toxicity was reported as average of 3 cell lines @ 50% cell death and the reference was QC with a toxicity value of 33.0 
uM. (extracted from An J et al, J Immunol 2015 [112]) 
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